Choksi Laboratories Limited Survey No. 9/1., Near Madhuri Refineries Balaji Tulsiyana Industrial Park, Kumedi, Off. M.R. 10 Toll Naka, Indore - 452010, M.P. (India) Tel. +91 731 3501112 (60 Lines)

CIN - L85195MP1993PLC007471



Scrip Code: 526546

Date: 10th February, 2021 To, Bombay Stock Exchange Limited. PhirozeJeejeebhoy Towers, Rotunda Bldg, Dalal Street, Mumbai- 400 051

Dear Sir/Madam,

Subject: Outcome of Board Meeting Ref: Scrip Code: 526546, ISIN: INE493D01013.

Meeting started at 03.30 P.M. and concluded at 04.30 P.M.

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 this is to inform you that following businesses were transacted at the meeting of the Board of Directors of the Company held on Wednesday, the 10th day of February, 2021 at 03:30 P.M. at the registered office of the Company situated at Survey No. 9/1, Tulsiyana Industrial Park, Kumedi, Indore-452010, M.P.

- 1. Approved and taken on record stand alone Unaudited Financial Results along with Limited review report by the statuary auditors of the Company for the guarter and Nine Month ended on 31st December 2020;
- 2. Approved the appointment of Ms. Surabhi Agrawal, Practicing Company Secretary for conducting Secretarial audit and compliance Report for the Financial Year 2020-21;

This is for your information and record.

Thanking You

For CHOKSI LABORATORIES LIMITED

SUNIL CHOKSI

MANAGING DIRECTOR

DIN: 00155078

Encl: Unaudited Financial Results for the quarter and Nine Month ended on 31st, December 2020

E-mail: vapi@choksilab.com

SUBHASH CHAND JAIN ANURAG & ASSOCIATES

CHARTERED ACCOUNTANTS
104, ARCHANA APARTMENT
8-B, RATLAM KOTHI, INDORE – 452 001 (MP)
PH # 2519439, 2527682 FAX # 0731 2519116
Email: scjainca2004@yahoo.com



Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors
Choksi Laboratories Limited
Indore (M.P.)-452001

- 1. We have reviewed the accompanying statement of unaudited financial results of Choksi Laboratories Limited ("the Company") for the quarter ended December 31, 2020 ("the Statement") and year to date from April 01, 2020 to December 31, 2020 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended (the "Listing Regulations').
- 2. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. This statement has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34) prescribed under section 133 of the Companies Act, 2013 read with rule 3 of Companies (Indian Accounting Standard) rules 2015, as amended read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410,"Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatements. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



4. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard (Ind AS) specified under section 133 of the companies act 2013 as amended read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the listing Regulation, including the manner in which it is to be disclosed, or that it contains any material misstatement.

INDORE

For Subhash Chand Jain Anurag & Associates

Chartered Accounts FRN: 004733C

Date: 10.02.2021 Place: Indore

(S.C. Jain) Partner

M.No. 072 062

UDIN: 21072062AAAAAD6396

Choksi Laboratories Limited Survey No. 9/1., Near Madhuri Refineries Balaji Tulsiyana Industrial Park, Kumedi, Off. M.R. 10 Toli Naka, Indore - 452010, M.P. (India) Tel. +91 731 3501112 (60 Lines)

CIN - L85195MP1993PLC007471



(ANALYTICAL TESTING & CALIBRATION LABORATORY GROUP)

CHOKSI LABORATORIES LTD.

Registered Office : Survey No 9/1, Tulsiyana Industrial Park, Kumedi, Indore (MP) 452 010

| | PARTICULARS | Quarter Ended | | | NI N | 4. 5. 1. 1. | (Rs. In Lakt | | | | | | | | |
|---|--|----------------------------|--------------|--|------------------|---|-----------------------|----|--|-------------|-------------|-------------|-------------|-------------|-----------|
| Sl. No. | | 3 Months ended Preceding 3 | | | Nine Month Ended | | Year Ended | | | | | | | | |
| | | 31.12.2020 | months ended | Corresponding 3 months ended in the previous year 31.12.2019 | figures for the | Year to Date figures for the previous period ended | Previous Yea ended | | | | | | | | |
| | | | | | | | | 1 | Personal Control | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Audited) |
| | | | | | | | | II | Revenue from Operation Other Income | 616.70 | 737.12 | 674.80 | 1834.32 | 2191.29 | 281 |
| | | | | | | | | | | 21.12 | 4.50 | 36.08 | 46.25 | 37.05 | 3 |
| | | | | | | | | IV | Total Revenue from operations (net) (I+II) | 637.82 | 741.62 | 710.88 | 1880.57 | 2228.34 | 284 |
| | | | | | | | | | Expenses | | | | | | 201 |
| (a) Cost of materials consumed | 55.36 | 76.20 | 66.32 | 191.70 | 256.21 | 324 | | | | | | | | | |
| (b) Employee benefits expense | 290.08 | 343.22 | 314.45 | 833.74 | 972.51 | 128: | | | | | | | | | |
| (c) Finance Cost | 68.37 | 70.24 | 52.93 | 197.06 | 152.00 | 189 | | | | | | | | | |
| (d) Depreciation and amortisation expense | 113.77 | 108.70 | 116.75 | 334.63 | 347.82 | 456 | | | | | | | | | |
| (e) Laboratories Maintainance Expenses | 84.24 | 70.77 | 59.66 | 197.70 | 191.03 | 250 | | | | | | | | | |
| (f) Power & Fuel Charges | 18.19 | 18.90 | 18.37 | 53.60 | 61.74 | 7 | | | | | | | | | |
| (g) Other expenses | 107.53 | 113.68 | 142.66 | 310.15 | 414.94 | | | | | | | | | | |
| | Total expenses | 737.54 | 801.71 | 771.14 | 2118.58 | 2396.25 | 588 | | | | | | | | |
| V | Profit/(Loss) before exceptional items and tax (III-IV) | (99.72) | (60.09) | (60.26) | (238.01) | | 317 | | | | | | | | |
| VI I | Exceptional items | (****-) | (00.05) | (00.20) | (238.01) | (167.91) | (328 | | | | | | | | |
| /II | Profit/(Loss) before tax (V-VI) | (99.72) | (60.09) | (60.26) | (229.01) | | 243 | | | | | | | | |
| (| Tax Expenses | (22.12) | (00.03) | (00.20) | (238.01) | (167.91) | (571. | | | | | | | | |
| | a) Current Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | | | | | | | | | |
| | b) Deferred Tax | 8.11 | (22.50) | (8.00) | 0.00 | 0.00 | 0 | | | | | | | | |
| X I | Profit/(Loss) for the period (VII-VIII) | (107.83) | (37.59) | | (16.24) | (22.05) | (182. | | | | | | | | |
| | Other Comprehensive Income | (107.03) | (37.39) | (52.26) | (221.77) | (145.86) | (388. | | | | | | | | |
| () p () | a) (i) Items that will not be reclassified to profit & loss | 2.50 | 2.50 | 0.25 | | | | | | | | | | | |
| | (ii) Income tax relating to items that will not be reclassified to | 2.30 | 2.50 | 0.35 | 7.50 | 1.05 | 21.4 | | | | | | | | |
| | profit & loss | (0.65) | (0.65) | | (1.05) | | | | | | | | | | |
| | b) (i) Items that will be re-classified to profit & loss | (0.05) | (0.03) | | (1.95) | - | (5.: | | | | | | | | |
| | (ii) Income tax relating to items that will be reclassified to | | - | - | - | - | | | | | | | | | |
| | profit & loss | | | | | | | | | | | | | | |
| T I | otal Comprehensive Income (IX+X) | (105.98) | (35.74) | (51.91) | (216.22) | (144.01) | | | | | | | | | |
| | Details of Equity Share Capital | (10000) | (55.74) | (31.91) | (210.22) | (144.81) | (372.5 | | | | | | | | |
| (8 | a) Paid-up equity share capital | 696.52 | 696.52 | 696.52 | 606.52 | (0) 50 | | | | | | | | | |
| (1 | b) Face value of equity share capital | 10.00 | 10.00 | 10.00 | 696.52 | 696.52 | 696.5 | | | | | | | | |
| III E | arnings per equity share (for continuing operation) | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 | 10.0 | | | | | | | | |
| | a) Basic | (1.55) | (0.54) | (0.75) | (2.10) | | | | | | | | | | |
| (t | D) Diluted | (1.55) | (0.54) | (0.75) | (3.18) | (2.09) | (5.5 | | | | | | | | |
| VE | arnings per equity share (for discontinued operation) | (1.55) | (0.34) | (0.75) | (3.18) | (2.09) | . (5.5 | | | | | | | | |
| (a | i) Basic | | | | | | | | | | | | | | |
| | D) Diluted | • | | | - | - | | | | | | | | | |
| XV E: or (a | arnings per equity share (for discontinued and continuing | | - | - | - | - | | | | | | | | | |
| | peration) | | | | | | | | | | | | | | |
| |) Basic | 1.55 | | | | | | | | | | | | | |
| |) Diluted | -1.55 | -0.54 | -0.75 | (3.18) | (2.09) | (5.5) | | | | | | | | |
| 10 | 7 | (1.55) | (0.54) | (0.75) | (3.18) | (2.09) | (5.5 | | | | | | | | |

Baroda Laboratory:

829 GIDC, Makarpura Baroda - 390 010 (Guj.) INDIA Mobile no.: 081550 59016/17/18/19 Fax: +91-265-3935123 E-mail: baroda@choksilab.com

Bengaluru Laboratory:

Siddhi Vinayaka Complex, Plot No. 8, 2nd Phase, Near BDA Complex 80 feet Ring Road, Nagarabhavi BENGALURE 560 079 (Karnataka) E-mail: bangalore@shoksilab.com Tel.: +91 080-23186929

Goa Laboratory : C-18,C-20 Verna Industrial Estate Phase - 1 A, Verna - 403722 (Goa) INDIA

Tel.: +91 8380033301-05 TeleFax: +91 8380033301-05 E-mail: goa@choksilab.com

Panchkula Laboratory:

Plot No. 362, Industrial Area, Phase - II Panchkula - 734 112 (Haryana) Tel.: +91-172-5048600, 5048601 Fax: +91-172-5048602 E-mail: panchkula@choksilab.com

Vapi Laboratory:

Ilnd& IIInd Floor, Gokul Complex, 101/8, GIDC-Char Rasta Behind GIDC Office, Vapi -396 195 (Guj.) INDIA Tel.: +91-260-2433488, 2434061, 2432731

Fax: +91-260-2432728 E-mail: vapi@choksilab.com

Choksi Laboratories Limited Survey No. 9/1., Near Madhuri Refineries Balaji Tulsiyana Industrial Park, Kumedi, Off. M.R. 10 Toll Naka, Indore - 452010, M.P. (India) Tel. +91 731 3501112 (60 Lines)

CIN - L85195MP1993PLC007471



Note

- 1 These results have been prepared as per Regulation 33 of the SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 and in accordance with the Indian Accounting Standards (Ind AS) notified under Section 133 of the Companies Act, 2013, read with the Companies (Indian Accounting Standards) Rules 2015 as amended and other accounting principles generally accepted in India.
- 2 "Other Income" for the quarter and Nine month ended on 31 December 2020 includes :-Interest Income at fair value as per IND AS Rs. 1,27,199.00, Interest on Deposits Rs. 52,014.00, Interest on IT refund Rs. 40,41,109.00, Prior Period Income (GST) Rs. 4,03,950.00
- The Company continues to consider the impact of COVID-19 pandemic in assessing the recoverability of receivables, 3 and intangible assets. For this purpose, the Company considered internal and external sources of information up to the date of approval of these financial results. The Company based on its judgements, estimates and assumptions including sensitivity analysis expects to fully recover the canying amount of receivables, intangible assets, and other assets. The Company will continue to closely monitor any material changes to future economic conditions.
- The figures for the quarter and nine month ended on 31st December, 2020 are the balancing figures between 4 unaudited figures in respect of the nine month ended on December 31, 2020 and the published unaudited figures for the half year ended on September 30, 2020
- 5 The above Financial Results for the quarter and nine month ended on 31st December 2020 have been reviewed by the Audit Committee and approved & taken on record by the Board at their Board meeting held on Wednesday, 10th February 2021.
- 6 The results for the quarter and nine month ended on 31st December 2020 are subject to "Limited Review" by the Statutory Auditors and their report contains no qualification.
- 7 Depreciation on fixed assets is provided on straight line method as per the estimated remaining useful life of assets.
- 8 The Company has identified "Analysis and Testing" as the single operating segment for the continued operations in the financial statements as per Ind AS 108 "Operating Segments".
- 9 Figures for the previous periods have been regrouped, wherever necessary and minus figures are shown in brackets.
- 10 Revenue from Operations is recorded exclusive of GST
- 11 Earnings per share amount shown in Rupees.
- 12 For any queries e_mail at compliance_officer@choksilab.com

Place: Indore Date : 10.02.2021

By Order of the Board

For Choksi Laboratories Limited

Managing Director

DIN: 00155078

829 GIDC, Makarpura Baroda - 390 010 (Guj.) INDIA Mobile no.: 081550 59016/17/18/19 Fax: +91-265-3935123 E-mail: baroda@choksilab.com

E-mail: bangalore@choksilab.com Tel.: +91 080-23186929

C-18,C-20 Verna Industrial Estate Phase - 1 A, Verna - 403722 (Goa) INDIA Tel.: +91 8380033301-05

TeleFax: +91 8380033301-05 E-mail: goa@choksilab.com

Panchkula Laboratory:

Plot No. 362, Industrial Area, Phase - II Panchkula - 734 112 (Haryana Tel.: +91-172-5048600, 5048601 Fax: +91-172-5048602

E-mail: panchkula@choksilab.com

Vapi Laboratory:

IInd & IIInd Floor, Gokul Complex, 101/8 GIDC-Char Rasta Behind GIDC Office, Vapi -396 195 (Guj.) INDIA Tel.: +91-260-2433488, 2434061, 2432731 Fax: +91-260-2432728

E-mail: vapi@choksilab.com